About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

359,057 studies
in
219 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/21/2021.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/21/2021.

Neural Mechanisms of Cannabinoid-impaired Decision-Making in Emerging Adults

Clinicaltrials.gov identifier NCT03944954

Recruitment Status Recruiting

First Posted May 10, 2019

Last update posted May 12, 2020

Study Description

Brief summary:

Emerging adults are a particularly vulnerable group for experiencing the immediate and potentially lifelong negative impacts of habitual cannabis use, and trends suggest that cannabis use disorder (CUD) will soon escalate in this population. The proposed research will combine clinical pharmacology, non-invasive brain stimulation, and neuroimaging techniques to establish the brain mechanisms of cannabinoid-impaired decision-making processes in emerging adults with CUD. Results from this project will inform CUD prevention/treatment efforts in this high-risk group and address a growing public health concern.

  • Condition or Disease:Neurosciences
    Substance-Related Disorders
    Behavior Problem
  • Intervention/Treatment: Drug: Marinol
    Device: Transcranial Magnetic Stimulation
  • Phase: Early Phase 1
Detailed Description

This mentored career development award (K01) will enable Dr. Michael J. Wesley to achieve his long-term goal of becoming an independent investigator with a clinical research program examining cannabis use disorder (CUD) in emerging adults, which is a current NIDA funding priority. Dr. Wesley is a new Assistant Professor at the University of Kentucky (UK) College of Medicine. The activities proposed in this award build on Dr. Wesley's background in neuroimaging and drug abuse research and will allow him to accomplish these specific short-term objectives: Become an expert in (1) clinical pharmacology and (2) non-invasive brain stimulation research, and enhance/develop his (3) knowledge of the responsible conduct of research, (4) skills for scientific communication and grant writing, and (5) ability to manage an independent research program. UK has numerous faculty and projects focused on drug abuse research and is an ideal environment for Dr. Wesley to successfully complete this award. Dr. Wesley has assembled a stellar mentoring team consisting of Dr. Josh Lile (Mentor), who runs a successful NIH-funded clinical pharmacology research program at UK and Drs. Mark George (Co-Mentor) and Colleen A. Hanlon of the Brain Stimulation Laboratory at the Medical University of South Carolina, Together they will guide and oversee Dr. Wesley's training in clinical pharmacology, brain stimulation, and scientific communication and grant writing. Dr. Wesley has proposed to engage in a series of formal classes, lab exchanges, and research seminars/meetings that will assist him in accomplishing the objectives of this award. The proposed research project is novel, innovative, and rigorous. It will combine the acute administration of Δ9-tetrahydrocannabinol (THC), the main psychoactive ingredient in cannabis, with brain stimulation and neuroimaging to examine the role of the dorsal lateral prefrontal cortex (DLPFC) and connected brain areas in drug-impaired decision-making processes. Specifically, transcranial magnetic stimulation (TMS) will be used to raise or lower DLPFC functionality following the administration THC in randomized, double-blind, placebo- and sham-controlled experiments. Aim 1 will test the hypotheses that excitatory TMS (raising DLPFC functionality; Exp. 1) will attenuate, whereas inhibitory TMS (lowering DLPFC functionality; Exp.2) will enhance, the impairing effects of THC on study outcomes. Aim 2 will use neuroimaging to test the hypothesis that individual differences in brain structure and function predict the specific and/or combined effects of THC and TMS on study outcomes. Results from this project will improve the investigator's understanding of the mechanisms involved in cannabis-impaired decision-making, which will inform CUD management and address a growing public health concern.

Study Design
  • Study Type: Interventional
  • Estimated Enrollment: 40 participants
  • Allocation: Randomized
  • Intervention Model: Parallel Assignment
  • Intervention Model Description: All individuals will receive multiple doses of oral THC (0, 10 and 30mg). Additionally, group 1 will receive excitatory TMS and group 2 will receive inhibitory TMS (real and sham in each group).
  • Masking: Single (Investigator)
  • Primary Purpose: Basic Science
  • Official Title: Neural Mechanisms of Cannabinoid-impaired Decision-Making in Emerging Adults
  • Actual Study Start Date: July 2017
  • Estimated Primary Completion Date: June 2023
  • Estimated Study Completion Date: June 2023
Arms and interventions
Arm Intervention/treatment
Experimental: Excitatory TMS
Combinations of THC and excitatory TMS.
Drug: Marinol
Individuals will receive 0, 10, 30mg of Marinol.

Device: Transcranial Magnetic Stimulation
Individuals will receive excitatory or inhibitory TMS
Experimental: Inhibitory TMS
Combinations of THC and inhibitory TMS.
Drug: Marinol
Individuals will receive 0, 10, 30mg of Marinol.

Device: Transcranial Magnetic Stimulation
Individuals will receive excitatory or inhibitory TMS
Outcome Measures
  • Primary Outcome Measures: 1. Learning Rate [ Time Frame: 4 Years ]
    In a Probabilistic Reinforcement Learning Choice (PRLC) task, two stimuli are presented and choosing either could result in a monetary reinforcer, but the reinforcement probabilities of the stimuli differ, and change throughout the task. Individuals attempt to optimize choices according to learned probabilities and track changing probabilities over time. PRLC performance allows mathematical modeling of trial-by-trial data under "real-world" uncertainty and yields computational parameters, such as the learning rate. Learning rates should favor recent changes in the experience of rewards so that individuals may have up-do-date representations of the world and reduced influence of irrelevant information while problem solving. We expect excitatory transcranial magnetic stimulation of the dorsal lateral prefrontal cortex, a brain area engaged by problem solving, to reduce the negative impact of increasing doses of THC on learning rates.
Eligibility Criteria
  • Ages Eligible for Study: 18 to 34 Years (Adult)
  • Sexes Eligible for Study: All
  • Accepts Healthy Volunteers: No
Criteria

Inclusion Criteria:

- Habitual cannabis use problems

- Body Mass Index ≤30

Exclusion Criteria:

- Past or current serious physical or mental health

- Sesame seed oil allergy

- Irregular health issues identified by the Study Physician

- Standard magnetic resonance imaging and transcranial magnetic stimulation exclusion
criteria (e.g., metal implants, history of epilepsy, etc.)

- Lack of affective form of birth control (females)

- Pregnancy (females)

Contacts and Locations
Contacts

Contact: Miranda P Ramirez, BS 859-323-0579 miranda.ramirez@uky.edu

Locations

United States, Kentucky
Neurobehavioral Systems Lab of the University of Kentucky College of Medicine
Lexington

Sponsors and Collaborators

University of Kentucky

Investigators

Principal Investigator: Michael J Wesley, PhD University of Kentucky

More Information
  • Responsible Party: University of Kentucky
  • ClinicalTrials.gov Identifier: NCT03944954 History of Changes
  • Other Study ID Numbers: K01DA043652
  • First Posted: May 10, 2019 Key Record Dates
  • Last Update Posted: May 12, 2020
  • Last Verified: May 2020
  • Studies a U.S. FDA-regulated Drug Product: Yes
  • Studies a U.S. FDA-regulated Device Product: Yes
  • Product Manufactured in and Exported from the U.S.: Yes
  • Additional relevant MeSH terms: Substance-Related Disorders Problem Behavior